Adenovirus-Inspired Virus-Like-Particles Displaying Melanoma Tumor Antigen Specifically Target Human DC Subsets and Trigger Antigen-Specific Immune Responses.
C-type lectin receptors
adenovirus
immunotherapy
melanoma
vaccine platform
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
10 Nov 2022
10 Nov 2022
Historique:
received:
13
09
2022
revised:
24
10
2022
accepted:
02
11
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Virus-like particles constitute versatile vectors that can be used as vaccine platforms in many fields from infectiology and more recently to oncology. We previously designed non-infectious adenovirus-inspired 60-mer dodecahedric virus-like particles named ADDomers displaying on their surface either a short epitope or a large tumor/viral antigen. In this work, we explored for the first time the immunogenicity of ADDomers exhibiting melanoma-derived tumor antigen/epitope and their impact on the features of human dendritic cell (DC) subsets. We first demonstrated that ADDomers displaying tumor epitope/antigen elicit a strong immune-stimulating potential of human DC subsets (cDC2s, cDC1s, pDCs), which were able to internalize and cross-present tumor antigen, and subsequently cross-prime antigen-specific T-cell responses. To further limit off-target effects and enhance DC targeting, we engineered specific motifs to de-target epithelial cells and improve DCs' addressing. The improved engineered platform making it possible to display large antigen represents a tool to overcome the barrier of immune allele restriction, broadening the immune response, and paving the way to its potential utilization in humans as an off-the-shelf vaccine.
Identifiants
pubmed: 36359404
pii: biomedicines10112881
doi: 10.3390/biomedicines10112881
pmc: PMC9687312
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondation SILAB - Jean Paufique
ID : Prix de la fondation d'entreprise 2020
Références
Nat Rev Immunol. 2018 Mar;18(3):168-182
pubmed: 29226910
Nat Nanotechnol. 2019 Sep;14(9):891-901
pubmed: 31384037
Cell. 1993 Apr 23;73(2):309-19
pubmed: 8477447
Mol Ther. 2010 May;18(5):1046-53
pubmed: 20179681
Pharmacogenomics. 2020 Jun;21(9):637-645
pubmed: 32423288
Oncotarget. 2014 Dec 30;5(24):12472-508
pubmed: 25537519
Cell. 1991 Sep 20;66(6):1145-53
pubmed: 1913805
Curr Drug Targets. 2007 Oct;8(10):1116-25
pubmed: 17979671
Adv Cancer Res. 2013;119:421-75
pubmed: 23870514
FEBS Lett. 2006 Nov 13;580(26):6123-31
pubmed: 17055489
Biochemistry. 2002 Dec 3;41(48):14299-305
pubmed: 12450395
Front Immunol. 2019 Jan 22;10:2
pubmed: 30723467
J Hematol Oncol. 2020 Jun 29;13(1):84
pubmed: 32600470
Adv Virus Res. 2006;68:159-91
pubmed: 16997012
Br J Cancer. 2016 Feb 16;114(4):357-61
pubmed: 26766734
Bioconjug Chem. 2007 May-Jun;18(3):963-9
pubmed: 17348701
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7
pubmed: 22366317
Nat Biotechnol. 1997 Jan;15(1):52-6
pubmed: 9035106
Curr Opin Immunol. 2010 Apr;22(2):212-4
pubmed: 20338741
Org Biomol Chem. 2020 Jul 1;18(25):4763-4772
pubmed: 32608454
Nat Rev Cancer. 2014 Aug;14(8):559-67
pubmed: 24990523
Viruses. 2020 Jul 02;12(7):
pubmed: 32630840
Int J Cancer. 2006 May 15;118(10):2617-27
pubmed: 16353138
J Biomed Biotechnol. 2010;2010:541939
pubmed: 20224646
Nat Rev Mol Cell Biol. 2001 Mar;2(3):179-87
pubmed: 11265247
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Cancer Gene Ther. 2011 Apr;18(4):288-96
pubmed: 21183947
Mol Ther. 2022 May 4;30(5):1913-1925
pubmed: 35151843
Virus Genes. 2017 Oct;53(5):700-706
pubmed: 28702840
PLoS One. 2012;7(9):e45416
pubmed: 23028993
J Immunol. 2012 Mar 1;188(5):2102-10
pubmed: 22291187
Signal Transduct Target Ther. 2021 Nov 15;6(1):396
pubmed: 34782609
Int J Mol Sci. 2020 Jul 25;21(15):
pubmed: 32722514
Sci Adv. 2019 Sep 25;5(9):eaaw2853
pubmed: 31620562
Immunology. 2018 May;154(1):3-20
pubmed: 29313948
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12504-9
pubmed: 9770515
PLoS Pathog. 2021 May 20;17(5):e1009576
pubmed: 34015061
J Immunol Res. 2015;2015:450695
pubmed: 26839900
Mol Pharm. 2022 Jan 3;19(1):235-245
pubmed: 34927439
Front Immunol. 2018 Jul 02;9:1499
pubmed: 30013560